Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy

Miriam F. Weiss, Roger A. Rodby, Amy C. Justice, Donald E. Hricik, Edmund J. Lewis, Richard Rohde, Raymond P. Bain, J. K. Evans, T. R. Turlington, P. K. Burrows, J. Sheehan, M. Pohl, T. Berl, J. Lemann, S. Blumenthal, S. Bresnahan, L. Hebert, Norris Stanley Nahman, R. Rodby, J. McGillF. Whittier, D. Cattran, J. Hano, L. Hunsicker, D. Maxwell, J. Porush, S. Spitalewitz, K. Shapiro, S. Adler, N. Tolchin, L. Svetkey, Z. Sharon, B. Rausenbaum, J. Breyer, G. Shulman

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background. Patients with diabetic nephropathy experience a progressive and usually inexorable decline in renal function. The presence of the structurally defined advanced glycation end product (AGE) pentosidine on tissue and circulating proteins has been correlated with the severity of diabetic complications. Methods. To delineate a role for this AGE in the progression of diabetic nephropathy, glycohemoglobin and free and protein- bound pentosidine were measured in baseline stored serum and urine from a subgroup of patients with diabetes mellitus and proteinuria originally followed by the Collaborative Study Group Trial. To delineate a potential role for an immune-activation response to AGEs, the inflammatory markers, interleukin-6 (IL-6), C-reactive protein (CRP), and the monocyte activation marker neopterin were also measured at baseline. The patients chosen represented 67 subjects whose creatinine levels had 'doubled' over the course of the study whether or not they later were treated with captopril, and 67 paired 'non-doublers.' Results. Baseline disease activity, as manifested by glycohemoglobin, serum creatinine and degree of proteinuria was equal in the two groups, as was protein-bound pentosidine and the immune-markers IL-6 and CRP. At baseline the 'doublers' as compared to the 'non-doublers' had elevated serum levels of free pentosidine and neopterin. Baseline increases in these two parameters were also associated with an increased rate of 'doubling' of serum creatinine by the proportional hazards method. Conclusion. Differences in individual responsiveness to AGEs, as manifested by either the production of free pentosidine or its release from a protein- bound form, and by evidence of monocyte/macrophage activation, are associated with progression of diabetic nephropathy.

Original languageEnglish (US)
Pages (from-to)193-202
Number of pages10
JournalKidney International
Volume54
Issue number1
DOIs
StatePublished - Jan 1 1998

Fingerprint

Neopterin
Diabetic Nephropathies
Creatinine
Advanced Glycosylation End Products
Serum
Proteinuria
C-Reactive Protein
Monocytes
Interleukin-6
Proteins
Macrophage Activation
Captopril
Diabetes Complications
Individuality
Diabetes Mellitus
Biomarkers
pentosidine
Urine
Kidney

Keywords

  • Advanced glycation end products
  • Diabetic complications
  • Diabetic nephropathy
  • Neopterin
  • Pentosidine

ASJC Scopus subject areas

  • Nephrology

Cite this

Weiss, M. F., Rodby, R. A., Justice, A. C., Hricik, D. E., Lewis, E. J., Rohde, R., ... Shulman, G. (1998). Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Kidney International, 54(1), 193-202. https://doi.org/10.1046/j.1523-1755.1998.00982.x

Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. / Weiss, Miriam F.; Rodby, Roger A.; Justice, Amy C.; Hricik, Donald E.; Lewis, Edmund J.; Rohde, Richard; Bain, Raymond P.; Evans, J. K.; Turlington, T. R.; Burrows, P. K.; Sheehan, J.; Pohl, M.; Berl, T.; Lemann, J.; Blumenthal, S.; Bresnahan, S.; Hebert, L.; Nahman, Norris Stanley; Rodby, R.; McGill, J.; Whittier, F.; Cattran, D.; Hano, J.; Hunsicker, L.; Maxwell, D.; Porush, J.; Spitalewitz, S.; Shapiro, K.; Adler, S.; Tolchin, N.; Svetkey, L.; Sharon, Z.; Rausenbaum, B.; Breyer, J.; Shulman, G.

In: Kidney International, Vol. 54, No. 1, 01.01.1998, p. 193-202.

Research output: Contribution to journalArticle

Weiss, MF, Rodby, RA, Justice, AC, Hricik, DE, Lewis, EJ, Rohde, R, Bain, RP, Evans, JK, Turlington, TR, Burrows, PK, Sheehan, J, Pohl, M, Berl, T, Lemann, J, Blumenthal, S, Bresnahan, S, Hebert, L, Nahman, NS, Rodby, R, McGill, J, Whittier, F, Cattran, D, Hano, J, Hunsicker, L, Maxwell, D, Porush, J, Spitalewitz, S, Shapiro, K, Adler, S, Tolchin, N, Svetkey, L, Sharon, Z, Rausenbaum, B, Breyer, J & Shulman, G 1998, 'Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy', Kidney International, vol. 54, no. 1, pp. 193-202. https://doi.org/10.1046/j.1523-1755.1998.00982.x
Weiss, Miriam F. ; Rodby, Roger A. ; Justice, Amy C. ; Hricik, Donald E. ; Lewis, Edmund J. ; Rohde, Richard ; Bain, Raymond P. ; Evans, J. K. ; Turlington, T. R. ; Burrows, P. K. ; Sheehan, J. ; Pohl, M. ; Berl, T. ; Lemann, J. ; Blumenthal, S. ; Bresnahan, S. ; Hebert, L. ; Nahman, Norris Stanley ; Rodby, R. ; McGill, J. ; Whittier, F. ; Cattran, D. ; Hano, J. ; Hunsicker, L. ; Maxwell, D. ; Porush, J. ; Spitalewitz, S. ; Shapiro, K. ; Adler, S. ; Tolchin, N. ; Svetkey, L. ; Sharon, Z. ; Rausenbaum, B. ; Breyer, J. ; Shulman, G. / Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. In: Kidney International. 1998 ; Vol. 54, No. 1. pp. 193-202.
@article{bc5e082e6d514e7e950766defe4db60d,
title = "Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy",
abstract = "Background. Patients with diabetic nephropathy experience a progressive and usually inexorable decline in renal function. The presence of the structurally defined advanced glycation end product (AGE) pentosidine on tissue and circulating proteins has been correlated with the severity of diabetic complications. Methods. To delineate a role for this AGE in the progression of diabetic nephropathy, glycohemoglobin and free and protein- bound pentosidine were measured in baseline stored serum and urine from a subgroup of patients with diabetes mellitus and proteinuria originally followed by the Collaborative Study Group Trial. To delineate a potential role for an immune-activation response to AGEs, the inflammatory markers, interleukin-6 (IL-6), C-reactive protein (CRP), and the monocyte activation marker neopterin were also measured at baseline. The patients chosen represented 67 subjects whose creatinine levels had 'doubled' over the course of the study whether or not they later were treated with captopril, and 67 paired 'non-doublers.' Results. Baseline disease activity, as manifested by glycohemoglobin, serum creatinine and degree of proteinuria was equal in the two groups, as was protein-bound pentosidine and the immune-markers IL-6 and CRP. At baseline the 'doublers' as compared to the 'non-doublers' had elevated serum levels of free pentosidine and neopterin. Baseline increases in these two parameters were also associated with an increased rate of 'doubling' of serum creatinine by the proportional hazards method. Conclusion. Differences in individual responsiveness to AGEs, as manifested by either the production of free pentosidine or its release from a protein- bound form, and by evidence of monocyte/macrophage activation, are associated with progression of diabetic nephropathy.",
keywords = "Advanced glycation end products, Diabetic complications, Diabetic nephropathy, Neopterin, Pentosidine",
author = "Weiss, {Miriam F.} and Rodby, {Roger A.} and Justice, {Amy C.} and Hricik, {Donald E.} and Lewis, {Edmund J.} and Richard Rohde and Bain, {Raymond P.} and Evans, {J. K.} and Turlington, {T. R.} and Burrows, {P. K.} and J. Sheehan and M. Pohl and T. Berl and J. Lemann and S. Blumenthal and S. Bresnahan and L. Hebert and Nahman, {Norris Stanley} and R. Rodby and J. McGill and F. Whittier and D. Cattran and J. Hano and L. Hunsicker and D. Maxwell and J. Porush and S. Spitalewitz and K. Shapiro and S. Adler and N. Tolchin and L. Svetkey and Z. Sharon and B. Rausenbaum and J. Breyer and G. Shulman",
year = "1998",
month = "1",
day = "1",
doi = "10.1046/j.1523-1755.1998.00982.x",
language = "English (US)",
volume = "54",
pages = "193--202",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy

AU - Weiss, Miriam F.

AU - Rodby, Roger A.

AU - Justice, Amy C.

AU - Hricik, Donald E.

AU - Lewis, Edmund J.

AU - Rohde, Richard

AU - Bain, Raymond P.

AU - Evans, J. K.

AU - Turlington, T. R.

AU - Burrows, P. K.

AU - Sheehan, J.

AU - Pohl, M.

AU - Berl, T.

AU - Lemann, J.

AU - Blumenthal, S.

AU - Bresnahan, S.

AU - Hebert, L.

AU - Nahman, Norris Stanley

AU - Rodby, R.

AU - McGill, J.

AU - Whittier, F.

AU - Cattran, D.

AU - Hano, J.

AU - Hunsicker, L.

AU - Maxwell, D.

AU - Porush, J.

AU - Spitalewitz, S.

AU - Shapiro, K.

AU - Adler, S.

AU - Tolchin, N.

AU - Svetkey, L.

AU - Sharon, Z.

AU - Rausenbaum, B.

AU - Breyer, J.

AU - Shulman, G.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Background. Patients with diabetic nephropathy experience a progressive and usually inexorable decline in renal function. The presence of the structurally defined advanced glycation end product (AGE) pentosidine on tissue and circulating proteins has been correlated with the severity of diabetic complications. Methods. To delineate a role for this AGE in the progression of diabetic nephropathy, glycohemoglobin and free and protein- bound pentosidine were measured in baseline stored serum and urine from a subgroup of patients with diabetes mellitus and proteinuria originally followed by the Collaborative Study Group Trial. To delineate a potential role for an immune-activation response to AGEs, the inflammatory markers, interleukin-6 (IL-6), C-reactive protein (CRP), and the monocyte activation marker neopterin were also measured at baseline. The patients chosen represented 67 subjects whose creatinine levels had 'doubled' over the course of the study whether or not they later were treated with captopril, and 67 paired 'non-doublers.' Results. Baseline disease activity, as manifested by glycohemoglobin, serum creatinine and degree of proteinuria was equal in the two groups, as was protein-bound pentosidine and the immune-markers IL-6 and CRP. At baseline the 'doublers' as compared to the 'non-doublers' had elevated serum levels of free pentosidine and neopterin. Baseline increases in these two parameters were also associated with an increased rate of 'doubling' of serum creatinine by the proportional hazards method. Conclusion. Differences in individual responsiveness to AGEs, as manifested by either the production of free pentosidine or its release from a protein- bound form, and by evidence of monocyte/macrophage activation, are associated with progression of diabetic nephropathy.

AB - Background. Patients with diabetic nephropathy experience a progressive and usually inexorable decline in renal function. The presence of the structurally defined advanced glycation end product (AGE) pentosidine on tissue and circulating proteins has been correlated with the severity of diabetic complications. Methods. To delineate a role for this AGE in the progression of diabetic nephropathy, glycohemoglobin and free and protein- bound pentosidine were measured in baseline stored serum and urine from a subgroup of patients with diabetes mellitus and proteinuria originally followed by the Collaborative Study Group Trial. To delineate a potential role for an immune-activation response to AGEs, the inflammatory markers, interleukin-6 (IL-6), C-reactive protein (CRP), and the monocyte activation marker neopterin were also measured at baseline. The patients chosen represented 67 subjects whose creatinine levels had 'doubled' over the course of the study whether or not they later were treated with captopril, and 67 paired 'non-doublers.' Results. Baseline disease activity, as manifested by glycohemoglobin, serum creatinine and degree of proteinuria was equal in the two groups, as was protein-bound pentosidine and the immune-markers IL-6 and CRP. At baseline the 'doublers' as compared to the 'non-doublers' had elevated serum levels of free pentosidine and neopterin. Baseline increases in these two parameters were also associated with an increased rate of 'doubling' of serum creatinine by the proportional hazards method. Conclusion. Differences in individual responsiveness to AGEs, as manifested by either the production of free pentosidine or its release from a protein- bound form, and by evidence of monocyte/macrophage activation, are associated with progression of diabetic nephropathy.

KW - Advanced glycation end products

KW - Diabetic complications

KW - Diabetic nephropathy

KW - Neopterin

KW - Pentosidine

UR - http://www.scopus.com/inward/record.url?scp=7144264416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7144264416&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.1998.00982.x

DO - 10.1046/j.1523-1755.1998.00982.x

M3 - Article

C2 - 9648079

AN - SCOPUS:7144264416

VL - 54

SP - 193

EP - 202

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 1

ER -